Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

Inclusion Criteria: * Philadelphia chromosome positive or bcr-abl gene positive * Chronic Myelogenous Leukemia (CML) * Subjects must have primary or acquired resistance to imatinib mesylate or have intolerance of imatinib mesylate * Philadelphia Chromosome Positive Acute Lymphoblastic leukemia (Ph+ALL) * Subjects must have primary or acquired resistance to chemotherapy or have intolerance of chemotherapy * Performance status (general conditions) specified by the Eastern Cooperative Oncology Group: 0-2 * Men and women, ages 20 - 75 * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 3 months after the study in such a manner that the risk of pregnancy is minimized Exclusion Criteria: * Subjects who are eligible and willing to undergo transplantation at pre-study * Women who are pregnant or breastfeeding * Uncontrolled or significant cardiovascular disease * History of significant bleeding disorder unrelated to CML or ALL * Adequate hepatic function * Adequate renal function * Medication that increase bleeding risk * Medication that change heart rhythms * Subjects who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study